News

A partnership between the DOC and Durham Tech Community College is now taking that care out to the community through a joint DOC-Durham Tech Mobile Health Lab service that visits DOC patients at home—while providing residents with life lessons in equity.

Internal Medicine Resident (PGY-2), Nicole Dussault, MD, was recognized with the Southern Society for Clinical Investigatio

Letters must be received by 3/1 and nominees and recipients will be honored at Duke AHEAD’s annual Education Day on 3/24/2023

Daniella Zipkin, MD, associate professor of medicine in the division of General Internal Medicine, recently published “Teaching Evidence-Based Medicine: A Toolkit for Educators” with Springer. We chatted with Dr. Zipkin about her new book.

Please join us in congratulating Emory Buck, MD, Omar Martinez-Uribe, MD, and Amanda Broderick, MD

The 2022 AAAS Fellows class includes 506 scientists, engineers and innovators spanning 24 scientific disciplines who are being recognized for their scientifically and socially distinguished achievements. 

If you are a member of the Department of Medicine Faculty or GME trainee and are interested in becoming a Civility Champion, we would love to have you train in our upcoming sessions!  In our o

Developmental psychologist Keisha Leanne Bentley-Edwards, PhD, MA, is an associate professor in the division of General Internal Medicine, the Associate Director of Research and the Director of the Health Equity Working Group for Duke’s Samuel DuBois Cook Center on Social Equity, a scholarly collaborative that studies the causes and consequences of inequality and develops remedies for these disparities and their adverse effects.

Duke TeleHOPE was piloted in 2019 with the support of a Duke Innovation for Healthcare Improvement (DIHI) Grant with the goal of addressing high hospital readmission rates among nursing home patients

As chief operating officer at the Duke Human Vaccine Institute (DHVI), Thomas Denny is in the unique position of helping people fight flu and HIV, developing the next generation of COVID-19 vaccines, and all the while leading an annual $120 million enterprise.